Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Doiwala, Dehradun, Uttarakhand, India.
Department of Surgical Oncology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Doiwala, Dehradun, Uttarakhand, India.
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.
ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.
ER-/PR+ 是一种有争议的亚型,尚未被正式确认为乳腺癌的分子亚型。少数研究得出结论认为这种亚型并不存在,而是由于技术错误造成的,但相反,其他人认为它是一种不同的实体,对治疗和临床结果有不同的反应。了解这种亚型是否具有任何独特的组织形态学特征或预后也很重要。因此,目前报告了两例有争议的 ER-/PR+ 乳腺癌亚型病例,这两个病例均显示出神经内分泌分化。